Literature DB >> 15791434

The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.

Henryk Barthel1, Meg Perumal, John Latigo, Qimin He, Frank Brady, Sajinder K Luthra, Pat M Price, Eric O Aboagye.   

Abstract

PURPOSE: The aim of this study was to investigate the role of thymidine kinase 1 (TK1) protein in 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) positron emission tomography (PET) studies.
METHODS: We investigated the in vivo kinetics of [18F]FLT in TK1+/- and TK1-/- L5178Y mouse lymphoma tumours that express different levels of TK1 protein.
RESULTS: [18F]FLT-derived radioactivity, measured by a dedicated small animal PET scanner, increased within the tumours over 60 min. The area under the normalised tumour time-activity curve were significantly higher for the TK1+/- compared with the -/- variant (0.89+/-0.02 vs 0.79+/-0.03 MBq ml(-1) min, P=0.043; n=5 for each tumour type). Ex vivo gamma counting of tissues excised at 60 min p.i. (n=8) also revealed significantly higher tumour [18F]FLT uptake for the TK1+/- variant (6.2+/-0.6 vs 4.6+/-0.4%ID g(-1), P=0.018). The observed differences between the cell lines with respect to [18F]FLT uptake were in keeping with a 48% higher TK1 protein in the TK1+/- tumours versus the -/- variant (P=0.043). On average, there were no differences in ATP levels between the two tumour variants (P=1.00). A positive correlation between [18F]FLT accumulation and TK1 protein levels (r=0.68, P=0.046) was seen. Normalisation of the data for ATP content further improved the correlation (r=0.86, P=0.003).
CONCLUSION: This study shows that in vivo [18F]FLT kinetics depend on TK1 protein expression. ATP may be important in realising this effect. Thus, [18F]FLT-PET has the potential to yield specific information on tumour proliferation in diagnostic imaging and therapy monitoring.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15791434     DOI: 10.1007/s00259-004-1611-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Evaluation of the mouse lymphoma tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test.

Authors:  M Honma; M Hayashi; H Shimada; N Tanaka; S Wakuri; T Awogi; K I Yamamoto; N Kodani; Y Nishi; M Nakadate; T Sofuni
Journal:  Mutagenesis       Date:  1999-01       Impact factor: 3.000

2.  Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.

Authors:  G W Aherne; A Hardcastle; E Ward; D Dobinson; T Crompton; M Valenti; L Brunton; A L Jackman
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

3.  Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs.

Authors:  Jeffrey L Schwartz; Yasuko Tamura; Robert Jordan; John R Grierson; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

4.  Mutant frequencies and loss of heterozygosity induced by N-ethyl-N-nitrosourea in the thymidine kinase gene of L5178Y/TK(+/-)-3.7.2C mouse lymphoma cells.

Authors:  Tao Chen; Karen Harrington-Brock; Martha M Moore
Journal:  Mutagenesis       Date:  2002-03       Impact factor: 3.000

Review 5.  Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.

Authors:  T Owa; H Yoshino; K Yoshimatsu; T Nagasu
Journal:  Curr Med Chem       Date:  2001-10       Impact factor: 4.530

6.  Thymidine kinase isoenzymes in human malignant lymphoma.

Authors:  P H Ellims; M B Van der Weyden; G Medley
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

7.  The HIV replication inhibitor 3'-fluoro-3'-deoxythymidine blocks sialylation of N-linked oligosaccharides.

Authors:  S Olofsson; S Eriksson; A Karlsson; B Oberg
Journal:  Antiviral Res       Date:  1992-07-01       Impact factor: 5.970

8.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography.

Authors:  D L Francis; A Freeman; D Visvikis; D C Costa; S K Luthra; M Novelli; I Taylor; P J Ell
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

9.  Human thymidine kinase 1. Regulation in normal and malignant cells.

Authors:  B Munch-Petersen; L Cloos; H K Jensen; G Tyrsted
Journal:  Adv Enzyme Regul       Date:  1995

10.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.

Authors:  Andreas K Buck; Holger Schirrmeister; Martin Hetzel; Mareike Von Der Heide; Gisela Halter; Gerhard Glatting; Torsten Mattfeldt; Florian Liewald; Sven N Reske; Bernd Neumaier
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  40 in total

1.  A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine.

Authors:  Ning Guo; Jingping Xie; H Charles Manning; Natasha G Deane; M Sib Ansari; Robert J Coffey; John Gore; Ronald R Price; Ronald M Baldwin; J Oliver McIntyre
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 2.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

3.  Molecular imaging in animal models of disease--every little detail counts!

Authors:  Farrokh Pakzad; Peter J Ell; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08       Impact factor: 9.236

4.  Assessment of therapy response in malignant tumours with 18F-fluorothymidine.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09       Impact factor: 9.236

5.  Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.

Authors:  Seung Jin Lee; Jeong Seok Yeo; Haeng Jung Lee; Eun Jung Lee; Seog Young Kim; Se Jin Jang; Jong Jin Lee; Jin-Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

6.  Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Yuko Goto; Megumi Jinguji; Sadao Tanaka; Yoshihiko Fukukura; Atsushi Tani; Michiyo Higashi
Journal:  Eur Radiol       Date:  2014-08-13       Impact factor: 5.315

7.  [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.

Authors:  Nicolas Graf; Ken Herrmann; Barbara Numberger; Daniela Zwisler; Michaela Aichler; Annette Feuchtinger; Tibor Schuster; Hans-Jürgen Wester; Reingard Senekowitsch-Schmidtke; Christian Peschel; Markus Schwaiger; Ulrich Keller; Tobias Dechow; Andreas K Buck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-05       Impact factor: 9.236

8.  Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas.

Authors:  Aya Shinomiya; Nobuyuki Kawai; Masaki Okada; Keisuke Miyake; Takehiro Nakamura; Yoshio Kushida; Reiji Haba; Nobuyuki Kudomi; Yuka Yamamoto; Masaaki Tokuda; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-15       Impact factor: 9.236

9.  Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.

Authors:  Michelle S Bradbury; Dolores Hambardzumyan; Pat B Zanzonico; Jazmin Schwartz; Shangde Cai; Eva M Burnazi; Valerie Longo; Steven M Larson; Eric C Holland
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

10.  Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.

Authors:  Mette Munk Jensen; Kamille Dumong Erichsen; Fredrik Björkling; Jacob Madsen; Peter Buhl Jensen; Liselotte Højgaard; Maxwell Sehested; Andreas Kjær
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.